Biogen Inc (BIIB)
199.57
-2.42
(-1.20%)
USD |
NASDAQ |
Apr 25, 11:25
Biogen Cash from Investing (Quarterly): -652.30M for Dec. 31, 2023
Cash from Investing (Quarterly) Chart
Historical Cash from Investing (Quarterly) Data
| Date | Value |
|---|---|
| December 31, 2023 | -652.30M |
| September 30, 2023 | -1.742B |
| June 30, 2023 | -753.50M |
| March 31, 2023 | -953.00M |
| December 31, 2022 | -141.10M |
| September 30, 2022 | 1.672B |
| June 30, 2022 | 693.50M |
| March 31, 2022 | -648.00M |
| December 31, 2021 | -112.70M |
| September 30, 2021 | -233.60M |
| June 30, 2021 | -152.70M |
| March 31, 2021 | -64.70M |
| December 31, 2020 | -166.40M |
| September 30, 2020 | -52.40M |
| June 30, 2020 | -832.70M |
| March 31, 2020 | 442.90M |
| December 31, 2019 | 708.40M |
| September 30, 2019 | -365.90M |
| June 30, 2019 | -110.80M |
| March 31, 2019 | 238.80M |
| December 31, 2018 | -1.625B |
| September 30, 2018 | -619.10M |
| June 30, 2018 | -1.148B |
| March 31, 2018 | 1.347B |
| December 31, 2017 | -769.50M |
| Date | Value |
|---|---|
| September 30, 2017 | -1.247B |
| June 30, 2017 | -202.50M |
| March 31, 2017 | -744.20M |
| December 31, 2016 | -581.70M |
| September 30, 2016 | 36.20M |
| June 30, 2016 | -736.10M |
| March 31, 2016 | -1.203B |
| December 31, 2015 | -1.808B |
| September 30, 2015 | -990.00M |
| June 30, 2015 | -1.253B |
| March 31, 2015 | -502.80M |
| December 31, 2014 | -378.30M |
| September 30, 2014 | -540.56M |
| June 30, 2014 | -630.13M |
| March 31, 2014 | 5.993M |
| December 31, 2013 | -710.01M |
| September 30, 2013 | -324.39M |
| June 30, 2013 | -726.24M |
| March 31, 2013 | 155.94M |
| December 31, 2012 | -375.45M |
| September 30, 2012 | -522.39M |
| June 30, 2012 | -53.12M |
| March 31, 2012 | 0.618M |
| December 31, 2011 | -389.53M |
| September 30, 2011 | -587.18M |
Cash From Investing Definition
Cash from Investing is a major line item of the statement of cash flows. This metric tracks the movement of cash flows for the overall investing activities of the company. A few examples of investing activities include net change in PP&E, and net divestitures.
Cash from Investing (Quarterly) Range, Past 5 Years
-1.742B
Minimum
Sep 2023
1.672B
Maximum
Sep 2022
-182.37M
Average
-152.70M
Median
Jun 2021
Cash from Investing (Quarterly) Benchmarks
| Eli Lilly and Co | -2.924B |
| Bristol-Myers Squibb Co | -1.346B |
| Gilead Sciences Inc | -727.00M |
| AbbVie Inc | -800.00M |
| Regeneron Pharmaceuticals Inc | -66.20M |
Cash from Investing (Quarterly) Related Metrics
| Cash from Operations (Quarterly) | 12.50M |
| Cash from Financing (Quarterly) | -646.10M |
| Free Cash Flow | 1.236B |
| Free Cash Flow Per Share (Quarterly) | -0.3612 |
| Free Cash Flow to Equity (Quarterly) | 295.50M |
| Free Cash Flow to Firm (Quarterly) | -11.98M |
| Free Cash Flow Yield | 4.26% |